<DOC>
	<DOCNO>NCT00002837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining peripheral stem cell transplantation chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness high-dose combination chemotherapy peripheral stem cell transplantation treat patient recurrent metastatic breast cancer .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Define maximum tolerate dos four course doxorubicin ( DOX ) , paclitaxel ( TAX ) , cyclophosphamide ( CTX ) follow peripheral blood stem cell ( PBSC ) granulocyte colony-stimulating factor support give out-patient setting patient metastatic breast cancer . II . Evaluate cardiotoxicity combination bolus DOX , 3-hour infusion TAX , CTX . III . Determine clinical response rate time progression associate regimen . IV . Determine Cmax , AUC drug : metabolite ratio TAX DOX give CTX , know p450 inducer . OUTLINE : Patients without prior doxorubicin ( DOX ) paclitaxel ( TAX ) receive two course induction chemotherapy DOX/TAX G-CSF support give 3 week apart . Peripheral blood stem cell ( PBSC ) harvest recovery phase follow second course . Patients previous receive DOX TAX respond receive cyclophosphamide ( CTX ) G-CSF stem cell mobilization follow PBSC harvest . Back-up bone marrow may harvest patient without marrow involvement PBSC collection inadequate . Patients respond stable disease adequate PBSC available receive dose-intensive chemotherapy DOX , CTX , TAX give day 1 , PBSC infuse day 3 G-CSF give day 3 neutrophil recovery . Four course dose-intensive chemotherapy PBSC G-CSF support give every 3-4 week . During phase I portion study , group 3-6 patient treat increase dos DOX , TAX , CTX maximum tolerate dose ( MTD ) determine ; phase II portion , additional patient treat MTD . Patients progress 2 course induction 2 course dose-intensive chemotherapy give option receive PBSC condition different regimen ( e.g. , CTX , etoposide , cisplatin ) . Patients receive induction protocol choose receive dose-intensive chemotherapy continue DOX/TAX total 6 course . Patients follow 3 , 6 , 12 , 18 , 24 month therapy , clinically indicate . PROJECTED ACCRUAL : During phase I portion study , group 3-6 patient enter dose level study . During phase II portion study , 25 patient treated maximum tolerate dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer metastatic recurrent Poorprognosis status require Phase I portion study , i.e . : Estrogen receptor progesterone receptornegative tumor OR Failed hormonal therapy bulky disease liver metastasis Bone marrow involvement le 15 % No active CNS metastases PATIENT CHARACTERISTICS : Age : 15 60 Sex : Not specify Performance status : Zubrod 0 1 Hematopoietic : WBC great 3,500/mm3 Absolute granulocyte count great 2,000/mm3 Platelet count great 100,000/mm3 Hepatic : Liver function test less twice normal Renal : Creatinine clearance ( calculate ) least 60 mL/min Cardiovascular : Left ventricular ejection fraction great 50 % No symptomatic cardiac disease require antiarrhythmic inotropic therapy Pulmonary : DLCO great 50 % predict Other : No preexist peripheral neuropathy great grade 1 No severe concomitant medical psychiatric disease PRIOR CONCURRENT THERAPY : Biologic therapy : More 3 week since immunotherapy Chemotherapy : No prior doxorubicin paclitaxel Patients 150 mg per square meter doxorubicin 4 course paclitaxel respond disease eligible doseintensive portion protocol therapy Endocrine therapy : Not specify Radiotherapy : More 3 week since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>